A phase II study of paclitaxel plus carboplatin as first‐line chemotherapy for women with metastatic breast carcinoma

Perez, Edith A.; Hillman, David W.; Stella, Philip J.; Krook, James E.; Hartmann, Lynn C.; Fitch, Tom R.; Hatfield, Alan K.; Mailliard, James A.; Nair, Suresh; Kardinal, Carl G.; Ingle, James N.

doi:10.1002/(sici)1097-0142(20000101)88:1<124::aid-cncr17>3.3.co;2-6

Cited by 23 publications

(28 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Severe side effects were infrequent. In general, the toxicity profile of the three regimens was similar to that shown in previously reported phase II studies with these regimens in patients with MBC [3][4][5][6][7][8][9]. The combination of gemcitabine and docetaxel was more myelotoxic than the other two regimens, while paclitaxel containing combinations were more neurotoxic.…”

Section: Discussionsupporting

confidence: 80%

“…Twenty-one patients were found ineligible. Reasons for ineligibility were: RFI less than a year (9 patients), history of other cancer (2), no evidence of metastatic disease at study entry (4), PS = 3 (2), and history of previous chemotherapy for MBC (4). A total of 416 eligible patients were included in the analysis according to the ITT principle.…”

Section: Eligibilitymentioning

confidence: 99%

“…Three of them, paclitaxel and carboplatin [3,4], docetaxel and gemcitabine [5,6] and weekly paclitaxel [7][8][9] have demonstrated significant activity and manageable toxicity. Furthermore, the first of these combinations was found to be effective in a phase III trial [10], when compared to the combination of paclitaxel and epirubicin, in terms of overall response rate (ORR), survival and quality of life (QoL).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer

Fountzilas

Dafni

Dimopoulos

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 80%

Section: Eligibilitymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer

Fountzilas

Dafni

Dimopoulos

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

“…Both Intaxel and Taxol demonstrated comparative response rates after 3 and 6 cycles (p > 0.05) The average response rate which was achieved in our study patients was 50%-60%. In various clinical trials, paclitaxel, in combination with carboplatin or doxorubicin for metastatic breast cancer, showed similar response rates [11,[17][18][19]. Similar response rates were observed with the paclitaxel therapy in metastatic breast cancer patients with and without a prior exposure to anthracyclines [14].…”

Section: Discussionmentioning

confidence: 56%

“…With the emergence of the taxanes as one of the most effective classes of treatment for breast cancer, clinical trials were conducted to determine the efficacy and the safety of the anthracycline/taxane combinations [7][8][9]. Doxorubicin or carboplatin, combined with paclitaxel, have shown good efficacy in the previously treated patients with metastatic breast cancer [1,[10][11]. The available data and experiences with the paclitaxelbased therapy in patients with advanced breast cancer indicate that the treatment may cause regression of the tumour and also delay the time till the disease progression [10][11][12][13][14][15].…”

Section: Introductionmentioning

confidence: 99%

A Comparative Analysis on the Efficacy and Safety of Intaxel® and Taxol® in Advanced Metastatic Breast Cancer

Láng

Rubovszky

Horváth

et al. 2013

JCDR

View full text Add to dashboard Cite

Background: Among the presently available cytotoxic drugs, paclitaxel, in combination with doxorubicin and carboplatin, come under the highly active therapy for metastatic breast cancer. Between the two brands of paclitaxel (Intaxel, which is marketed by Fresenius Kabi and Taxol, the original paclitaxel which is manufactured by BMS) the similarity has not been evaluated in clinical trial settings till date. This prospective, controlled, randomized, multicentre, open-label phase IV study was planned to compare the safety and efficacy of Intaxel with Taxol, when they were used in combination with carboplatin or doxorubicin, as a second line treatment for metastatic breast cancer. Methods:Fourty nine eligible patients were randomized to receive Intaxel or Taxol with either doxorubicin or carboplatin. The patients who had received a prior anthracycline based chemotherapy were randomized to the paclitaxel/carboplatin arm. The patients were evaluated in three phases i.e. at baseline, during the treatment and at follow up for the tumour response, the time period till the disease progression and the toxicity. The time till the disease progression was assessed by the KaplanMeier method. The continuous and categorical variables were assessed by using the ANOVA test and Fisher's exact test, respectively.Results: After 3 cycles, an objective response rate of 55.56% (CR = 3, PR = 7) was noted in the Intaxel group and that of 59.09% (CR = 1, PR = 12) was noted in the Taxol group. After 6 cycles, an objective response rate of 50% was noted in both the groups. No significant difference was observed in the response rate of the two groups after 3 cycles (p > 0.05) and at the end of the treatment (p > 0.05). The patients who received Intaxel had a lower incidence of thrombocytopaenia (p = 0.0146) and neurosensory loss (p = 0.008) as compared to those who received Taxol. Conclusion:The results of this study demonstrated that the safety and efficacy of Intaxel and Taxol are equivalent when they are used in combination with other cytotoxic agents as the second line of treatment for metastatic stage IV breast cancer.

show abstract

Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy

Walsh

Shalaby

O’Loughlin

et al. 2018

Breast Cancer Res Treat

View full text Add to dashboard Cite

PurposeThe rate of pathological complete response (pCR) for patients with triple negative breast cancer (TNBC) is increased when carboplatin is added to neo-adjuvant chemotherapy (NACT). However, while phase III trial data showing a survival benefit are awaited, carboplatin is not yet standard-of-care for TNBC. The aim of this study was to examine the rate of pCR and the outcome for those treated with carboplatin and to examine the predictors of response to therapy.MethodsThe retrospective series comprised 333 consecutive patients with TNBC (median follow-up time, 43 months). Adjuvant chemotherapy was given to 51% (n = 168) of patients and 29% (n = 97) received anthracycline–taxane NACT with carboplatin given to 9% (n = 31) of patients.ResultsOverall, 25% (n = 78) of patients experienced a breast cancer recurrence and 22% (n = 68) died from disease. A pCR breast and pCR breast/axilla was more common in those who received carboplatin (n = 18, 58% and n = 17, 55%, respectively) compared those who did not (n = 23, 36% and n = 18, 28%, respectively) (p = 0.041 and p = 0.011, respectively). By multivariable analysis, carboplatin and high tumor grade were independent predictors of pCR breast/axilla (ORnon-pCR = 0.17; 95% CI 0.06–0.54; p = 0.002; and ORnon-pCR = 0.05, 95% CI 0.01–0.27; p < 0.001, respectively). pCR breast/axilla was an independent predictor of DFS (HRnon-pCR=6.23; 95% CI 1.36–28.50; p = 0.018), metastasis-free survival (HRnon-pCR = 5.08; 95% CI 1.09–23.65; p = 0.038) and BCSS (HRnon-pCR = 8.52; 95% CI 1.09–66.64; p = 0.041).ConclusionCarboplatin therapy and high tumor grade are associated with a significant increase in the rate of pCR, which is an independent predictor of outcome. These data support the use of carboplatin in NACT for TNBC, while results from phase III studies are awaited.Electronic supplementary materialThe online version of this article (10.1007/s10549-018-5066-6) contains supplementary material, which is available to authorized users.

show abstract

A phase II study of paclitaxel plus carboplatin as first‐line chemotherapy for women with metastatic breast carcinoma

Cited by 23 publications

References 14 publications

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer

A Comparative Analysis on the Efficacy and Safety of Intaxel® and Taxol® in Advanced Metastatic Breast Cancer

Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy

Contact Info

Product

Resources

About